A pilot study conducted at Be Well Hospital in Chennai, India, has unveiled the potential of Nichi-BBRITE Beta glucans, a food supplement derived from the AFO-202 strain of Aureobasidium Pullulans, as a revolutionary addition to Parkinson’s disease treatment. Patients who participated in the study experienced significant improvements in their Unified Parkinson’s Disease Rating Scale (UPDRS) and constipation scores after a 90-day course of Nichi-BRITE.
Parkinson’s disease, a devastating neurological condition, impacts millions of individuals worldwide. Emerging research is uncovering the critical connection between gut health and neurological disorders like Parkinson’s. Nichi-BRITE Beta glucans have been found to regulate harmful gut bacteria while promoting the proliferation of beneficial microbiota.
Dr. Dedeepiya, a co-author of the study, expressed optimism about Nichi-BRITE’s potential as an adjunct therapy for synucleinopathies such as Parkinson’s disease and multiple system atrophy. Dr. Nithyanandam, the study’s neurologist, emphasized the importance of more comprehensive studies to further investigate Nichi-BRITE’s potential.
During a World Parkinson’s Day webinar, Prof. Muralidhar Hegde from Houston Methodist Research, USA, spoke about the significance of alpha-synuclein abnormalities in the development of neurodegenerative diseases. Dr. Rukmini Mridula from Hyderabad highlighted the growing prevalence of young-onset Parkinson’s disease in India.
The promising results from this pilot study suggest that Nichi-BRITE Beta glucans could soon emerge as an essential component in the management of Parkinson’s disease, offering hope and improved treatment options for millions of patients around the world.
Author
